Vidac Pharma · raw details

Skin Cancer Treatment · Jerusalem · Founded 2012

active Public ← back to profile

Highlights

1 patent

About

Skin Cancer Treatment

Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines to help people with a range of oncologic and dermatologic diseases. The companys technology targets the VDAC/HK2 system unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue. Vidacs lead drug, VDA-1102, has successfully completed a phase 2b clinical trial in actinic keratosis (AK) as an investigational new drug under the FDA and is currently in a phase 2a clinical trial in CTCL in Israel. The company is also developing VDA-1275, a potent small-molecule new chemical entity that selectively modulates the novel VDAC/HK2 mechanism of action. It is highly potent in vitro against a broad range of tumor types and demonstrates significant selectivity for the VDAC/HK2 system over the VDAC/HK1 system. VDA-1275 is chemically unrelated to VDA-1102 and presents a different set of pharmacokinetic characteristics. It is being developed as a systemic drug for the treatment of solid tumors. Vidac was founded by Professor Max Herzberg. The company has licensed part of its technology from Tel Aviv University and Ben Gurion University.

Identity

NameVidac Pharma
Slugvidac-pharma
Type / kindstartup
Crunchbase IDvidac-pharma
Source _idagxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6_0ucLDA

Status

Statusactive
Status reasonPublic on Hamburg Stock Exchange on Mar, 2023<br>
Last update2026-05-17

Location

HQ country codeIL
HQ region/districtJerusalem District
HQ cityJerusalem
HQ addressHartom Street 10, Jerusalem, Israel

Web & social

Websitehttps://vidacpharma.com/en
LinkedInhttps://www.linkedin.com/company/3121139
Twitter / Xhttps://twitter.com/VidacPharma

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharma-companiesoncologyoral-drugstargeted-therapydrug-discoverybiotechnologydermatologydrug-developmenttopical-treatmentcancerbiopharmaceutical

Funding

Total raised$9.0M
Current stagePublic

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}